Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

No single score captures the burden of treatment in people with cystic fibrosis (pwCF), according to systematic review study findings published in the Journal of Cystic Fibrosis.

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

It is their job to stay up to date on the latest cystic fibrosis treatment guidelines and new medications and therapies. They often work in specialized cystic fibrosis centers and collaborate with ...

I spent my childhood and young adulthood being told I was “too young and healthy” to be dealing with the health issues I experienced. But as an adult, I was determined to find answers, and eventually, ...

New Delhi, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The global liver fibrosis treatment market was valued at USD 17.51 billion in 2024 and is projected to reach USD 51.16 billion by 2033, growing at a ...

In October 2024, Trevi Therapeutics company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF ...